Supplementary Table S1. Comparison of results from GC-MS and GC-MS/MS using Passing-Bablok regression and Bland-Altman procedure (1 pooled serum sample from non-pregnant subjects, and sera from 4 adult men, 4 women in follicular phase, 4 women in luteal phase, 4 women at labor, and 4 samples from mixed umbilical blood at labor were analyzed).

Steroid abbreviation	Matrix	r^a	Intercept (95 % CI)	Slope (95 % CI)	Difference (95 % CI)	Range	
						GC-MS	GC-MS/MS
Preg	MFLPU	0.994	-0.16 (-0.93, 0.29)	0.93 (0.84, 1.1)	-0.71 (-1.2, -0.25) *	2.1 - 27	2 - 24
PregC	MFLPU	0.976	-120 (-190, 1.7)	0.96 (0.74, 1.2)	-45 (-220, 130)	35 - 4900	29 - 5600
DHPreg20α	MFLPU	0.760	1 (-0.4, 1.6)	0.83 (0.58, 1.3)	0.42 (0.069, 0.78) *	1.2 - 5.2	1.9 - 5.7
DHPreg20αC	MFLPU	0.965	140 (-46, 220)	0.9 (0.76, 1.1)	-6.1 (-110, 93)	260 - 3000	230 - 2600
Preg16α	MFLPU	0.974	0.018 (-0.065, 0.067)	1 (0.8, 1.3)	-0.017 (-0.32, 0.29)	0.11 - 9.3	0.11 - 7.6
DHEA	MFLPU	0.995	0.25 (-0.41, 0.51)	1.1 (0.98, 1.2)	0.66 (0.38, 0.93) *	1.9 - 15	2.3 - 16
DHEAC	MFLPU	0.987	-92 (-260, 230)	1.2 (1, 1.3)	250 (150, 360) *	620 - 6300	530 - 6600
DHEA7α	MFLPU	0.951	0.24 (0.074, 0.5) *	1.1 (0.81, 1.4)	0.33 (0.18, 0.47) *	0.35 - 3.9	0.6 - 3.7
DHEA7β	MFLPU	0.993	-0.13 (-0.39, -0.052) *	0.91 (0.8, 1.4)	-0.23 (-0.34, -0.11) *	0.25 - 6.2	0.15 - 5.2
5-Adiol	MFLPU	0.964	0.13 (-0.17, 0.46)	1.4 (1.1, 1.9) *	0.61 (0.4, 0.81) *	0.18 - 5.3	0.25 - 6.3
5-AdiolC	MFLPU	0.988	120 (-7.7, 220)	1.1 (0.98, 1.2)	290 (130, 440) *	230 - 5800	310 - 6000
AT7α	MFLPU	0.969	-0.05 (-0.1, -0.022) *	1 (0.89, 1.2)	-0.05 (0.077, -0.023)	0.046 - 0.81	0.013 - 0.82
AT7β	MFLPU	0.958	-0.072 (-0.095, -0.029)*	1.1 (0.79, 1.2)	-0.07 (-0.091, -0.049) *	0.064 - 0.49	0.0031 - 0.45
P	MFLPU	0.999	-1.2 (-2.6, 0.24)	0.95 (0.91, 0.98)*	-31 (-63, -0.12) *	0.22 - 2300	0.072 - 2100
P16α	MFLPU	0.999	-0.41 (-0.64, -0.31) *	0.94 (0.88, 1)	-0.25 (-1.7, 1.2)	0.49 - 230	0.13 - 240
A4	MFLPU	0.974	-0.27 (-0.81, 0.041) *	1.3 (1.1, 1.5) *	0.71 (0.12, 1.3) *	1.2 - 10	1.2 - 12
T	MFLPU	0.954	-1.1 (-1.5, -0.46) *	1.3 (0.84, 1.6)	0.39 (-0.99, 1.8) *	0.61 - 21	0.21 - 30
DHT5α	MFLPU	0.820	-0.032 (-0.13, 0.047)	1.1 (0.59, 1.4)	-0.011 (-0.13, 0.11)	0.018 - 1.6	0.035 - 1.4
E2	LPU	0.979	-0.27 (-3.4, 0.27)	1.5 (1.1, 1.7) *	7.6 (-1, 16)	0.33 - 60	0.2 - 96
E2C	LPU	0.937	0.27 (-0.29, 5.4)	0.99 (0.73, 1.6)	1.4 (-2.2, 5)	0.33 - 46	0.2 - 45
DHP5α	PU	0.969	-8.7 (-68, 43)	1.5 (0.99, 2.3)	38 (7.2, 70) *	24 - 200	27 - 260
THP3α5α	PU	0.789	5.3 (-250, 18)	0.81 (0.23, 13)	0.6 (-2.4, 3.6)	18 - 30	19 - 30
THP3α5αC	MFLPU	0.971	-8.8 (-14, -3) *	1.2 (0.91, 1.3)	11 (-30, 53)	7.9 - 1200	1.2 - 1200
THP3β5αC	MFLPU	0.948	-4.7 (-8.2, -0.66) *	1.2 (0.94, 1.3)	56 (-28, 140)	3.3 - 920	2.9 - 1600

Supplementary Table S1., continued.

Steroid abbreviation	Matrix	r^a	Intercept (95 % CI)	Slope (95 % CI)	Difference (95 % CI)	Range GC-MS	Range GC-MS/MS
THP3β5β	MFLPU	0.940	-0.28 (-0.45, -0.056) *	1.2 (0.46, 1.8)	0.048 (-0.3, 0.4)	0.14 - 2.5	0.0091 - 3.9
THP3β5βC	MFLPU	0.977	-6 (-8.5, -3.5) *	1.1 (0.97, 1.3)	5 (-7.3, 17)	1.4 - 260	0.21 - 330
THP5α20α	MFLPU	0.945	0.96 (-0.68, 1.1)	1.4 (1, 1.9)	6.6 (1.6, 12) *	0.057 - 78	0.7 - 91
THP5β20α	MFLPU	0.984	-0.16 (-0.37, -0.09) *	1.3 (1.1, 1.8)*	2.1 (-0.08, 4.2)	0.028 - 51	0.024 - 58
PD3α5α20α	PU	0.962	-4.4 (-13, 1.7)	1.1 (0.65, 1.5)	-3.5 (-6, -1.1) *	7.8 - 29	3.6 - 28
PD3α5α20αC	MFLPU	0.964	1.7 (-12, 4.7)	1.2 (1.1, 1.6) *	680 (-20, 1400)	11 - 6400	10 - 10000
PD3β5α20αC	MFLPU	0.951	56 (-460, 270)	0.98 (0.84, 1.3)	3300 (-6800, 13000)	180 - 170000	220 - 220000
PD3α5β20αC	MFLPU	0.974	-3.8 (-11, 2.9)	1.2 (1, 1.3)	200 (-39, 430)	1.5 - 3600	4.4 - 4300
PD3β5β20αC	MFLPU	0.962	-13 (-38, 1)	1.1 (0.9, 1.6)	93 (-14, 200)	5.4 - 2100	7.9 - 2300
THA3α5α	MFLPU	0.923	0.062 (0.0067, 0.14) *	0.87 (0.58, 1.1)	-0.0078 (-0.078, 0.062)	0.15 - 1.4	0.19 - 1.1
THA3α5αC	MFLPU	0.987	53 (0.67, 190) *	1 (0.88, 1.1)	47 (-55, 150)	23 - 4500	30 - 3700
THA3β5αC	MFLPU	0.990	56 (28, 86) *	1.1 (0.96, 1.2)	93 (59, 130) *	52 - 1600	90 - 1900
THA3α5β	MFLPU	0.960	0.025 (0.07, 0.082) *	0.96 (0.73, 1.3)	-0.0049 (-0.037, 0.027)	0.12 - 1.1	0.1 - 1.1
THA3α5βC	MFLPU	0.997	0.42 (4.7, 4.3) *	1 (0.96, 1.1)	1.3 (-1.8, 4.3)	6.7 - 360	5.6 - 370
THA3β5βC	MFLPU	0.996	0.05 (-0.42, 2)	0.92 (0.79, 0.98)*	-1.7 (-4.1, 0.67)	0.39 - 210	0.39 - 200
AD3α5α17β	MFLPU	0.990	-0.026 (-0.045, -0.002) *	1.3 (1, 1.4) *	0.019 (-0.012, 0.051)	0.044 - 0.52	0.029 - 0.64
AD3α5α17βC	FLPU	0.774	6.3 (-5.9, 16)	0.79 (0.37, 1.3)	1.6 (-4.4, 7.5)	2.2 - 64	9.2 - 63
AD3β5α17β	MFLPU	0.754	-0.043 (-0.17, -0.00026)*	1.5 (0.92, 3.1)	0.005 (-0.016, 0.026)	0.044 - 0.2	0.043 - 0.27
AD3β5α17βC	MFLPU	0.995	2 (-0.46, 6.2)	1 (0.97, 1.1)	5.9 (1.5, 10) *	3.9 - 360	4.6 - 340

* Intercept and difference between method significantly different from zero and slope significantly different from 1. Results are shown in nmol/l. [a] correlation coefficient between results from GC-MS and GC-MS/MS. M, F, L, P, and U represent inclusion of samples from men, women in luteal phase, women in follicular phase, pregnant women and umbilical cord blood, respectively.